ALLAN A. ORENSTEIN, M.D.; VINCENT YAKULIS, B.S.; JOSEPH EIPE, M.D.; NICOLAS COSTEA, M.D.
This content is PDF only. Please click on the PDF icon to access.
A number of adverse effects have been reported in association with hydralazine therapy including hyperdynamic circulation with increased heart rate and cardiac output, an acute rheumatoid state resembling disseminated lupus erythematosus, peripheral neuropathy, and various blood dyscrasias (1). Although a number of drugs have been shown to trigger immune hemolytic anemia (2, 3), hydralazine was not one of them; however, we have recently observed a patient who developed Coombs' positive hemolysis while receiving small doses of this drug for mild hypertension.
A 63-year-old white man was referred to us in July 1976 for evaluation of anemia. He was asymptomatic, without
ORENSTEIN AA, YAKULIS V, EIPE J, COSTEA N. Immune Hemolysis Due to Hydralazine. Ann Intern Med. 1977;86:450–451. doi: 10.7326/0003-4819-86-4-450
Download citation file:
Published: Ann Intern Med. 1977;86(4):450-451.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use